Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.

Autor: Lyke KE; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: klyke@som.umaryland.edu., Chua JV; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Koren M; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Friberg H; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Gromowski GD; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Rapaka RR; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Waickman AT; Department of Microbiology and Immunology, State University of New York Update Medical University, Syracuse, NY, USA., Joshi S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Strauss K; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., McCracken MK; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Gutierrez-Barbosa H; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Shrestha B; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Culbertson C; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Bernal P; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., De La Barrera RA; Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Currier JR; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Jarman RG; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Edelman R; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Aug; Vol. 24 (8), pp. 896-908. Date of Electronic Publication: 2024 Apr 25.

RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects.

Autor: Sneller L; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Lin C; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Price A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Kottilil S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Chua JV; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Publikováno v: Microorganisms [Microorganisms] 2024 Mar 17; Vol. 12 (3). Date of Electronic Publication: 2024 Mar 17.

Increased risk of severe COVID-19 in pregnancy in a multicenter propensity score-matched study.

Autor: Cojocaru L; Division of Anesthesia Critical Care, Department of Anesthesiology, Perioperative Care, and Pain Medicine, New York University Grossman School of Medicine, New York, NY, USA.; Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, University of Maryland School of Medicine, Baltimore, MD, USA.; Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL, USA., Noe M; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Pahlavan A; Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD, USA., Werzen A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Seung H; Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA., Yoo YCJ; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Tyson P; Department of Obstetrics and Gynecology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Narayanan S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Turan S; Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, University of Maryland School of Medicine, Baltimore, MD, USA., Turan OM; Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, University of Maryland School of Medicine, Baltimore, MD, USA., Chua JV; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Publikováno v: Journal of perinatal medicine [J Perinat Med] 2023 Aug 21; Vol. 51 (9), pp. 1171-1178. Date of Electronic Publication: 2023 Aug 21 (Print Publication: 2023).

Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways.

Autor: Khanam A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. AKhanam@ihv.umaryland.edu., Ghosh A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Chua JV; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Kottilil S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Publikováno v: Journal of translational medicine [J Transl Med] 2023 Apr 21; Vol. 21 (1), pp. 271. Date of Electronic Publication: 2023 Apr 21.

A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection.

Autor: Price AS; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Nelson AK; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Ghosh A; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Kottilil S; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Chua JV; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Publikováno v: Journal of medical virology [J Med Virol] 2023 Jan; Vol. 95 (1), pp. e28105. Date of Electronic Publication: 2022 Sep 12.